(Q34768657)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12150848%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12150848%20AND%20SRC:MED&resulttype=core&format=json

eradication of infectious diseases

11 November 2019

main subject

anti-retroviral agent

0 references

1 reference

S M Blower

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12150848%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 August 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12150848%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12150848%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12150848%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12150848%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

487-493

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12150848%20AND%20SRC:MED&resulttype=core&format=json

Control strategies for tuberculosis epidemics: new models for old problems

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Global elimination of trachoma: how frequently should we administer mass chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

HIV-1 drug resistance in newly infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Transmission of antiretroviral-drug-resistant HIV-1 variants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

A tale of two futures: HIV and antiretroviral therapy in San Francisco.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Predicting the unpredictable: transmission of drug-resistant HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Health care policy. U.S. priorities-HIV prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Predicting and preventing the emergence of antiviral drug resistance in HSV-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

The intrinsic transmission dynamics of tuberculosis epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Impact of antivirals and emergence of drug resistance: HSV-2 epidemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Strategies for long-term success in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

An Investigation of Uncertainty and Sensitivity Analysis Techniques for Computer Models

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Modelling the effect of treatment and behavioral change in HIV transmission dynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Community treatment of HIV-1: initial stage and asymptotic dynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021

HIV prevention before HAART in sub-Saharan Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900346-8

7 January 2021